Bilski v. Kappos | GenomeWeb

Bilski v. Kappos

The higher court will consider whether two method patents held by Prometheus Laboratories claim natural phenomena and are therefore not patentable under the law.

Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.

Many in the genetic testing industry have viewed the Bilski decision as a harbinger of the Supreme Court's thinking for future patent cases, including the anti-gene patenting suit filed against Myriad Genetics.

The Supreme Court Justices' comments imply they are looking for a way to uphold the lower court's "machine-or-transformation" test in Bilski v. Kappos while minimizing the impact on the technology and medical device industries.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.